(4aR,7aS)-6-Methyloctahydropyrrolo[3,4-b][1,4]oxazine

Catalog No. :
ACFPUQ901
CAS No. :
1932611-72-7
Molecular Formula :
C7H14N2O
Molecular Weight :
142.20

IUPAC Name:(4aR,7aS)-6-methyloctahydropyrrolo[3,4-b][1,4]oxazine

(4aR,7aS)-6-Methyloctahydropyrrolo[3,4-b][1,4]oxazine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg98%$201.00Login to see priceInquiryInquiry
250mg98%$322.00Login to see priceInquiryInquiry
1g98%$806.00Login to see priceInquiryInquiry
5g98%$2418.00Login to see priceInquiryInquiry
10g98%$4030.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(4aR,7aS)-6-Methyloctahydropyrrolo[3,4-b][1,4]oxazine
IUPAC Name(4aR,7aS)-6-methyloctahydropyrrolo[3,4-b][1,4]oxazine
Molecular FormulaC7H14N2O
Molecular Weight142.20
SMILESCN(C1)C[C@@]2([H])[C@]1([H])NCCO2
InChI KeyHBQXTZXLQBSTCJ-RQJHMYQMSA-N
Synonym(4aR,7aS)-6-methyloctahydropyrrolo[3,4-b][1,4]oxazine;(4aS,7aR)-6-methyloctahydropyrrolo[3,4-b][1,4]oxazine;Pyrrolo[3,4-b]-1,4-oxazine, octahydro-6-methyl-, (4aS,7aR)-
CAS No.1932611-72-7

Safety Data

Pictogram
CorrosiveHarmful or irritant
Signal Word
Danger
Hazard Statement(s)
H302
Precautionary Statement(s)
P260-P264-P270-P271-P280-P301+P330+P331-P303+P361+P353-P304+P340-P305+P351+P338-P310-P363-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACFPUQ901 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACDTQJ324 route compound structure diagram
    ACDTQJ3247447-41-8 In Stock
  4. Then
  5. ACFPUQ901 route product structure diagram
    ACFPUQ9011932611-72-7
Inquiry

2. ACFPUQ901 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACFPUQ901 route product structure diagram
    ACFPUQ9011932611-72-7
Inquiry

Comments (0)